2001 | 2010 | EAPC 2001–2010 (95% CI) | |||
---|---|---|---|---|---|
n | Rate (95% CI) | n | Rate (95% CI) | ||
Age group (years) | |||||
Male | |||||
< 20 | 1 | 0.03 | 1 | 0.03 | 0 |
20–39 | 2 | 0.07 | 2 | 0.06 | −1.43 |
40–59 | 15 | 0.72 | 10 | 0.44 | −3.89 |
60+ | 26 | 3.16 | 26 | 2.88 | −0.89 |
Age standardized | 44 | 0.58 (0.41–0.76) | 39 | 0.48 (0.33–0.63) | 3.1 (−2.5–9.1) |
Female | |||||
< 20 | 2 | 0.06 | 2 | 0.06 | 0 |
20–39 | 197 | 6.42 | 263 | 7.78 | 2.12* |
40-59 | 952 | 44.6 | 1374 | 58.4 | 3.09* |
60+ | 396 | 48.1 | 755 | 74.8 | 5.55* |
Age standardized | 1547 | 17.3 (16.5–18.2) | 2401 | 24.7 (23.7–25.7) | 4.4 (3.3–5.5)* |
Overall age standardised rate | 1591 | 9.17 (8.17–9.62) | 2440 | 13.0 (12.5–13.5) | 4.4 (3.3–5.4) |
Histology type | |||||
Female | |||||
Ductal CA | 1221 | 13.6 (12.9–14.4) | 2085 | 21.4 (20.5–22.4) | 5.2 (2.8–7.8)* |
Lobular CA | 74 | 0.8 (0.6–1.0) | 55 | 0.6 (0.4–0.7) | −3.3 (− 10.4–19.2) |
Malignancy NOS | 158 | 1.8 (1.5–2.1) | 142 | 1.5 (1.2–1.7) | −0.9 (− 10.6–9.9) |
Others | 94 | 1.0 (0.8–1.3) | 119 | 1.2 (1.0–1.5) | 2.4 (−2.4–7.5) |
Male | |||||
Ductal CA | 32 | 0.43 (0.28–0.58) | 33 | 0.41 (0.27–0.55) | 3.2 (−3.3–10.3) |
Lobular CA | 2 | 0.02 (0.00–0.06) | 0 | 0.0 | – |
Malignancy NOS | 4 | 0.05 (0.00–0.10) | 3 | 0.04 (0.02–0.08) | 5.6 (− 12.1–26.9) |
Others | 6 | 0.08 (0.02–0.14) | 3 | 0.03 (0.00–0.07) | − 4.3 (− 20.3–15.1) |
Overall | |||||
Ductal CA | 1253 | 7.21 (6.82–7.64) | 2118 | 11.2 (10.8–11.7) | 5.2 (2.8–7.7)* |
Lobular CA | 76 | 0.44 (0.34–0.54) | 55 | 0.29 (0.21–0.36) | 2.6 (− 10.4–17.6) |
Malignancy NOS | 162 | 0.95 (0.82–1.13) | 145 | 0.78 (0.65–0.90) | −0.8 (− 10.8–10.3) |
Others | 100 | 0.57 (0.46–0.68) | 122 | 0.66 (0.54–0.78) | 2.8 (−2.5–8.3) |